Results 31 to 40 of about 18,508 (192)

Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism

Journal of Immunotoxicology, 2022
Dolutegravir is a highly potent HIV integrase strand transfer inhibitor that is recommended for first-line anti-retroviral treatment in all major treatment guidelines.
Morris Madzime, Annette J. Theron, Ronald Anderson, Gregory R. Tintinger, Helen C. Steel, Pieter W. A. Meyer, Jan G. Nel, Charles Feldman, Theresa M. Rossouw   +8 more
doaj   +1 more source

Adverse events of raltegravir and dolutegravir. [PDF]

, 2017
To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Prospective cohort study.
Battegay, Manuel, Bernasconi, Enos, Calmy, Alexandra, Cavassini, Matthias, Elzi, Luigia, Erb, Stefan, Furrer, Hansjakob, Günthard, Huldrych, Swiss HIV Cohort Study, Vernazza, Pietro   +9 more
core   +4 more sources

Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring [PDF]

, 2018
Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a ...
Appiah, Lambert T, Beloukas, Apostolos, Chadwick, David, Geretti, Anna Maria, Phillips, Richard O, Ruggiero, Alessandra, Sarfo, Fred S, Smith, Colette, Stockdale, Alexander J, Villa, Giovanni   +9 more
core   +3 more sources

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation

Viruses, 2020
With the current widespread use of dolutegravir in low-income countries, the understanding of the impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on the efficacy of dolutegravir-containing antiretroviral therapy (ART) is
Dominique L. Braun, Thomas Scheier, Ulrich Ledermann, Markus Flepp, Karin J. Metzner, Jürg Böni, Huldrych F. Günthard   +6 more
doaj   +1 more source

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2021
Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied ...
Zimasa Gcwabe, Kaneez Sayed, Charlotte Schutz, Olina Ngwenya, Eric Goemaere, Rene Goliath, Amanda Jackson, Rulan Griesel, Andrew Hill, Graeme Meintjes, Tali Cassidy, Claire Keene, Ying Zhao, Gary Maartens   +13 more
doaj   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen

South African Journal of Psychiatry, 2022
Although reports of neuropsychiatric side effects have been reported with efavirenz, these have been limited in comparison with regard to the now recommended dolutegravir regimens.
Ahmed Badat, Karishma Lowton
doaj   +1 more source

Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.

PLoS ONE, 2019
BackgroundNumerous randomized clinical trials (RCTs) were conducted to evaluate dolutegravir based triple antiretroviral therapy (ART) compared to other triple antiretroviral regimens in naïve patients, and a summary of the available evidence is required
Mario Cruciani, Saverio G Parisi
doaj   +1 more source

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]

, 2020
BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M   +9 more
core  

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes [PDF]

, 2014
To evaluate the replication capacity and phenotypic susceptibility to dolutegravir and raltegravir of wild-type and raltegravir-resistant HIV-1 strains in several cellular ...
Calvez, V, Ceccherini-Silberstein, F, Cortese, Mf, di Santo, F, Fabeni, L, Fedele, V, Malet, I, Marcelin, A-, Perno, CF, Pollicita, M, Surdo, M, Svicher, V   +11 more
core   +1 more source